Abstract
In order to discover compounds that may be useful in the prevention of Alzheimer disease, a drug library was screened for drugs that could decrease amyloid β peptide (Aβ) accumulation secreted from a human CNS-derived cell line. Of the 2160 compounds subjected to a primary screen, 16, or 0.74%, reduced Ab accumulation by at least 40%. Seven of these compounds were confirmed to be effective in a secondary screen using each compound at a dose of 5 μM. Three of these seven compounds were more effective than the others at reducing Aβ levels in a tertiary screen, and led to 68 to 85% reductions in total Aβ, at the 25 μM dosage. The effects of these three drugs on secreted Aβ40, Aβ42, and sAPPα were also determined. Thus, we have identified lead compounds that may be useful for subsequent studies to determine the mechanism of action of each drug, as well as for pre-clinical studies to determine whether each of these drugs is safe and effective in vivo.
Keywords: amyloid peptide, drug screen, amyloid precursor protein
Current Alzheimer Research
Title: Drug Library Screen to Identify Compounds that Decrease Secreted Aβ from a Human Cell Line
Volume: 2 Issue: 2
Author(s): Enakshi Chakrabarti and Jonathan D. Smith
Affiliation:
Keywords: amyloid peptide, drug screen, amyloid precursor protein
Abstract: In order to discover compounds that may be useful in the prevention of Alzheimer disease, a drug library was screened for drugs that could decrease amyloid β peptide (Aβ) accumulation secreted from a human CNS-derived cell line. Of the 2160 compounds subjected to a primary screen, 16, or 0.74%, reduced Ab accumulation by at least 40%. Seven of these compounds were confirmed to be effective in a secondary screen using each compound at a dose of 5 μM. Three of these seven compounds were more effective than the others at reducing Aβ levels in a tertiary screen, and led to 68 to 85% reductions in total Aβ, at the 25 μM dosage. The effects of these three drugs on secreted Aβ40, Aβ42, and sAPPα were also determined. Thus, we have identified lead compounds that may be useful for subsequent studies to determine the mechanism of action of each drug, as well as for pre-clinical studies to determine whether each of these drugs is safe and effective in vivo.
Export Options
About this article
Cite this article as:
Chakrabarti Enakshi and Smith D. Jonathan, Drug Library Screen to Identify Compounds that Decrease Secreted Aβ from a Human Cell Line, Current Alzheimer Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567205053585738
DOI https://dx.doi.org/10.2174/1567205053585738 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Detecting Gene-Gene Interactions Associated with Multiple Complex Traits with U-Statistics
Current Genomics Possible Neuroprotective Strategies for Huntingtons Disease
Current Neuropharmacology Interactions of Iron Oxide Nanoparticles with the Immune System: Challenges and Opportunities for their Use in Nano-oncology
Current Pharmaceutical Design Hemodynamic Monitoring in the Acute Management of Pediatric Heart Failure
Current Cardiology Reviews PAX6 expression may be protective against dopaminergic cell loss in Parkinson’s disease
CNS & Neurological Disorders - Drug Targets Author Index To Volume 1
Recent Patents on CNS Drug Discovery (Discontinued) Development of Vasculature Targeting Strategies for the Treatment of Chronic Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy Tryptamine Induces Axonopathy and Mitochondriopathy Mimicking Neurodegenerative Diseases via Tryptophanyl-tRNA Deficiency
Current Alzheimer Research Editorial [Hot Topic:Fluorine-Containing Drugs as PET Diagnostics (F-18 Labeled Tracers)]
Current Topics in Medicinal Chemistry Current Gene Expression Studies in Esophageal Carcinoma
Current Genomics Intravenous Magnesium – Lidocaine - Ketorolac Cocktail for Postoperative Opioid Resistant Pain: A Case Series of Novel Rescue Therapy
Reviews on Recent Clinical Trials Silver Nanoparticles: Synthesis, Antimicrobial Coatings, and Applications for Medical Devices
Recent Patents on Materials Science Phytoestrogen-Rich Dietary Supplements in Anti-Atherosclerotic Therapy in Postmenopausal Women
Current Pharmaceutical Design Variability in the Response to Non-pharmacological Treatments in Patients with Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine All in the Family: The TNF-TNFR Superfamily in the Pathogenesis and Treatment of Rheumatoid Arthritis and other Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Applications of Artificial Neural Networks in Medical Science
Current Clinical Pharmacology Commentary (Research Highlights: Transcranial Drug Delivery for Neurological Disorders)
CNS & Neurological Disorders - Drug Targets Trauma Interventions using Mindfulness Based Extinction and Reconsolidation (TIMBER<sup>©</sup>) as Monotherapy for Chronic PTSD: A Pilot Study
Adolescent Psychiatry Small Molecules that Promote Neurogenesis in vitro
Recent Patents on CNS Drug Discovery (Discontinued) Amyloid-β Inhibits PDGFβ Receptor Activation and Prevents PDGF-BBInduced Neuroprotection
Current Alzheimer Research